Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19

Autor: Gysi, Deisy Morselli, Valle, Ítalo Do, Zitnik, Marinka, Ameli, Asher, Gan, Xiao, Varol, Onur, Ghiassian, Susan Dina, Patten, JJ, Davey, Robert, Loscalzo, Joseph, Barabási, Albert-László

The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. In the past decade, network medicine has developed and

Externí odkaz: http://arxiv.org/abs/2004.07229

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Amidino-rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis.

Autor: Keiser PT; Department of Virology, Immunology, and Microbiology, Boston University Medical School, Boston, MA, 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA, 02118, USA., Zhang W; Boston University Center for Molecular Discovery (BU-CMD), Department of Chemistry, Boston University, Boston, MA, 02215, USA., Ricca M; Boston University Center for Molecular Discovery (BU-CMD), Department of Chemistry, Boston University, Boston, MA, 02215, USA., Wacquiez A; National Emerging Infectious Diseases Laboratories, Boston University, MA, 02118, USA; Department of Biochemistry and Cell Biology, Chobanian and Avedisian School of Medicine, Boston University, Boston, MA, 02118, USA., Grimins A; Department of Biochemistry and Cell Biology, Chobanian and Avedisian School of Medicine, Boston University, Boston, MA, 02118, USA., Cencic R; Department of Biochemistry, Department of Oncology and Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada, H3G 1Y6., Patten JJ; Department of Virology, Immunology, and Microbiology, Boston University Medical School, Boston, MA, 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA, 02118, USA., Shah P; National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, 20892, USA., Padilha E; National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, 20892, USA., Connor JH; Department of Virology, Immunology, and Microbiology, Boston University Medical School, Boston, MA, 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA, 02118, USA., Pelletier J; Department of Biochemistry, Department of Oncology and Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada, H3G 1Y6., Lyons SM; Department of Biochemistry and Cell Biology, Chobanian and Avedisian School of Medicine, Boston University, Boston, MA, 02118, USA., Saeed M; National Emerging Infectious Diseases Laboratories, Boston University, MA, 02118, USA; Department of Biochemistry and Cell Biology, Chobanian and Avedisian School of Medicine, Boston University, Boston, MA, 02118, USA., Brown LE; Boston University Center for Molecular Discovery (BU-CMD), Department of Chemistry, Boston University, Boston, MA, 02215, USA., Porco JA Jr; Boston University Center for Molecular Discovery (BU-CMD), Department of Chemistry, Boston University, Boston, MA, 02215, USA., Davey RA; Department of Virology, Immunology, and Microbiology, Boston University Medical School, Boston, MA, 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA, 02118, USA. Electronic address: radavey@bu.edu.

Publikováno v: Antiviral research [Antiviral Res] 2024 Oct; Vol. 230, pp. 105976. Date of Electronic Publication: 2024 Aug 06.

Single-cell image-based genetic screens systematically identify regulators of Ebola virus subcellular infection dynamics.

Autor: Carlson RJ; Massachusetts Institute of Technology, Department of Health Sciences and Technology, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Patten JJ; Department of Virology, Immunology, and Microbiology, Boston University School of Medicine, Boston, MA, USA.; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA., Stefanakis G; Laboratory for Information & Decision Systems, Massachusetts Institute of Technology, Cambridge, MA, USA., Soong BY; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Radhakrishnan A; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard School of Engineering and Applied Sciences, Cambridge, MA, USA., Singh A; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Thakur N; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Amarasinghe GK; Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA., Hacohen N; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital, Cancer Center, Boston, MA, USA., Basler CF; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Leung D; Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA., Uhler C; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Laboratory for Information & Decision Systems, Massachusetts Institute of Technology, Cambridge, MA, USA., Davey RA; Department of Virology, Immunology, and Microbiology, Boston University School of Medicine, Boston, MA, USA.; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA., Blainey PC; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Apr 07. Date of Electronic Publication: 2024 Apr 07.

A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential.

Autor: Bird GH; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Patten JJ; Department of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, 02118, USA., Zavadoski W; ATP R&D Labs, Branford, CT, 06405, USA., Barucci N; ATP R&D Labs, Branford, CT, 06405, USA., Godes M; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Moyer BM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Owen CD; Department of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, 02118, USA., DaSilva-Jardine P; Red Queen Therapeutics, Inc., Cambridge, MA, 02142, USA., Neuberg DS; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Bowen RA; Department of Biomedical Sciences, Colorado State University, Fort Collins, CO, 80523, USA., Davey RA; Department of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, 02118, USA., Walensky LD; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Loren_Walensky@dfci.harvard.edu.; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Loren_Walensky@dfci.harvard.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Jan 04; Vol. 15 (1), pp. 274. Date of Electronic Publication: 2024 Jan 04.